Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Insider Pascal Deschatelets Sells 12,000 Shares of Stock

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Get Rating) insider Pascal Deschatelets sold 12,000 shares of the company’s stock in a transaction dated Monday, May 8th. The shares were sold at an average price of $92.39, for a total transaction of $1,108,680.00. Following the transaction, the insider now owns 1,033,813 shares in the company, valued at $95,513,983.07. The sale was disclosed in a filing with the SEC, which is available at this hyperlink.

Pascal Deschatelets also recently made the following trade(s):

• On Monday, April 10th, Pascal Deschatelets sold 12,000 shares of Apellis Pharmaceuticals stock. The stock was sold at an average price of $78.21, for a total transaction of $938,520.00.
• On Wednesday, March 8th, Pascal Deschatelets sold 12,000 shares of Apellis Pharmaceuticals stock. The stock was sold at an average price of $63.79, for a total transaction of $765,480.00.
• On Wednesday, February 8th, Pascal Deschatelets sold 12,000 shares of Apellis Pharmaceuticals stock. The stock was sold at an average price of $54.45, for a total transaction of $653,400.00.

Apellis Pharmaceuticals Trading Down 2.1 %

NASDAQ:APLS opened at $89.47 on Wednesday. Apellis Pharmaceuticals, Inc. has a 52 week low of $33.32 and a 52 week high of $94.45. The firm has a 50 day moving average of $74.29 and a 200 day moving average of $60.15. The company has a quick ratio of 3.78, a current ratio of 4.29 and a debt-to-equity ratio of 0.55. The stock has a market capitalization of $9.96 billion, a price-to-earnings ratio of -14.27 and a beta of 1.23.

Apellis Pharmaceuticals (NASDAQ:APLS – Get Rating) last posted its quarterly earnings results on Thursday, May 4th. The company reported ($1.56) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.42) by ($0.14). The company had revenue of $44.80 million during the quarter, compared to analysts’ expectations of $26.10 million. Apellis Pharmaceuticals had a negative return on equity of 255.36% and a negative net margin of 652.50%. The company’s quarterly revenue was up 211.1% on a year-over-year basis. During the same period in the prior year, the business posted ($1.42) EPS. As a group, sell-side analysts anticipate that Apellis Pharmaceuticals, Inc. will post -5.22 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Clearstead Advisors LLC purchased a new position in shares of Apellis Pharmaceuticals in the first quarter worth $27,000. IFP Advisors Inc raised its holdings in shares of Apellis Pharmaceuticals by 49,525.0% in the first quarter. IFP Advisors Inc now owns 1,985 shares of the company’s stock worth $39,000 after buying an additional 1,981 shares during the last quarter. US Bancorp DE raised its holdings in shares of Apellis Pharmaceuticals by 391.2% during the first quarter. US Bancorp DE now owns 1,110 shares of the company’s stock worth $56,000 after purchasing an additional 884 shares during the last quarter. Parallel Advisors LLC raised its holdings in shares of Apellis Pharmaceuticals by 1,173.0% during the first quarter. Parallel Advisors LLC now owns 942 shares of the company’s stock worth $62,000 after purchasing an additional 868 shares during the last quarter. Finally, Point72 Hong Kong Ltd purchased a new position in shares of Apellis Pharmaceuticals during the third quarter worth $65,000. Hedge funds and other institutional investors own 87.26% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on the stock. Needham & Company LLC upped their target price on shares of Apellis Pharmaceuticals from $70.00 to $80.00 and gave the stock a “buy” rating in a research note on Tuesday, February 21st. Wells Fargo & Company upped their target price on shares of Apellis Pharmaceuticals from $55.00 to $76.00 in a research note on Friday, May 5th. HC Wainwright increased their price objective on shares of Apellis Pharmaceuticals from $87.00 to $100.00 in a research note on Friday, May 5th. Wedbush increased their price objective on shares of Apellis Pharmaceuticals from $51.00 to $67.00 and gave the company a “neutral” rating in a research note on Monday, April 17th. Finally, Citigroup increased their price objective on shares of Apellis Pharmaceuticals from $88.00 to $106.00 in a research note on Monday. Four equities research analysts have rated the stock with a hold rating, eight have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $88.79.

About Apellis Pharmaceuticals

(Get Rating)

Apellis Pharmaceuticals, Inc is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs. The company was founded by Candace Rose Depp, Pascal Deschatelets, Cedric Francois, and Alec Machiels on September 25, 2009 and is headquartered in Waltham, MA.